QuantHealth is transforming drug development through AI-powered simulations, making clinical trials safer, faster, and more accessible. Our platform enables pharmaceutical companies to run thousands of virtual trials in minutes, using data from millions of patients, therapeutics, molecules, and clinical studies, with an industry-leading predictive accuracy of 86%. We partner with leading pharma companies globally and continue to push the boundaries of how drugs are developed and brought to market.
We are looking for a Talent Acquisition Partner to join our team and support our growth. This is a recruitment-first role (around 90%), with additional exposure to HR (around 10%). You will lead end-to-end hiring processes, with a strong focus on engineering, product & science roles, working closely with hiring managers to attract and hire top talent.
You will manage multiple hiring processes simultaneously, with a strong focus on quality, speed, and candidate experience. You will build and execute creative sourcing strategies, including engaging top-tier and passive candidates. You will act as a trusted partner to stakeholders, providing market insights and hiring recommendations.
In parallel, you will gain hands-on HR experience, including working with HiBob, supporting employee lifecycle processes, and handling employment documents and amendments.
QuantHealth is an AI company conducting patient-centric drug simulations to accelerate and de-risk drug development. Over 90% of drugs in clinical development stage fail to reach the market, which accumulates to a $45B/year direct lost to the pharma and biotech industry. Our platform allows our pharma and biotech partners to rapidly run thousands of variations of their clinical trials to optimize the trial design and significantly increase the probability of trial success, all while enabling discovery of new clinical opportunities and optimization strategies. QuantHealth has one the largest integrated datasets that spans the clinical, pharmacological and biological domains together with a proprietary AI platform that can predict patient-response to both approved and novel therapies.
